Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Harmony Biosciences Holdings, Inc. keeps $29 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 54 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. develops and markets therapies for rare neurological conditions as a commercial-stage biotechnology company listed on the NASDAQ Global Market under the ticker HRMY. Its business today is centered on WAKIX in the United States, and it generated $868.5 million of revenue in FY2025.
Today's Snapshot
HRMY ended yesterday 1.1% down at 41.62.
Trading Volume
Above 10d avg 913.1K
1.1M
vs S&P 500 Today
Underperforming Market
-0.59%
Updated: September 10, 2026 at 12:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$34.60 - $41.10Buy
- RSI (14)61.51Neutral
- Stochastic %K (14, 3, 3)74.88Neutral
- MACD Level (12, 26)1.28Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.